Noom
For GLP-1 Users, Effort Could Be the Key Factor in Long-Term Health
New data from Noom suggests that people who put more effort into eating healthy and working out see the best results from weight-loss drugs.
New Study Reveals an Inconvenient Truth About Weight-Loss Drugs
GLP-1s deliver dramatic weight loss, but a new study reveals what happens when treatment stops and why weight often comes back fast.
ATN Week in Review: Gyms Face a Familiar Challenge
Big-box gyms and health clubs are acquiring new members (especially Gen Z) at a rapid clip, but they’re also struggling to keep them around.
Noom Eyes GLP-1s for Longevity, Not Just Weight Loss
Noom’s microdose GLP-1 program targets early metabolic risk and longevity, offering weight-loss drugs to adults with a BMI of 21 or higher.
GLP-1 Use Doubles Across America — Here’s Who’s Taking Them
New Gallup data shows GLP-1 use has doubled nationwide as telehealth startups and investors are reshaping the weight-loss market.
New ‘SkinGPT’ Tool Uses AI To Predict Facial Aging. Noom Is Its First Adopter
Noom teams up with Haut.AI to launch Future Me, a tool that lets users preview how lifestyle choices could visibly shape aging and wellness.
UBS Event Explores What’s Next in Booming Global Wellness Market
From AI wearables to GLP-1s and social fitness, UBS’s event spotlighted the innovations driving the $2 trillion wellness market.
Rebel Wilson, Noom Partner as GLP-1s Enter Microdose Era
Rebel Wilson joins Noom as chief wellness ambassador, backing its new free tier that gamifies healthy habits and spotlights microdose GLP-1s.
Noom Launches $119 Microdose GLP-1 Weight Loss Program
Noom’s microdose GLP-1 program says 70% of users report no side effects and lose up to 17 pounds in 60 days with behavior change support.
AgelessRx Adds Oral GLP-1 Drops
Longevity-focused telehealth platform Ageless Rx has added oral GLP-1 drops as a needle-free option for weight loss consumers.
